Extending therapeutic use of psychostimulants: Focus on serotonin-1A receptor

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 46, Issue , 2013, Pages 170-180

  Haleem, Darakhshan Jabeen ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

5 HT 1A receptors; Addiction; Amphetamine; Apomorphine; Dopamine; Psychosis

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; APOMORPHINE; COCAINE; DOPAMINE; METHAMPHETAMINE; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN AGONIST;

ADAPTATION; ADDICTION; ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BEHAVIOR; BEHAVIORAL SENSITIZATION; CATAPLEXY; COGNITIVE DEFECT; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG ABUSE; ERECTILE DYSFUNCTION; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; LIMBIC SYSTEM; NARCOLEPSY; NEUROMODULATION; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OBESITY; PRESCRIPTION; PSYCHOSIS; REVIEW; SENSITIZATION; SIDE EFFECT; SYNAPSE;

(S)-N-TERT-BUTYL-3-[4-(2-METHOXYPHENYL) PIPERAZIN-1-YL]-2-PHENYLPRO PANAMIDE; 5-HT; 5-HT-1A RECEPTORS; 5-HYDROXYTRYPTAMINE; 8-HYDROXY-2-(DI-N-PROPYLAMINO)-TETRALIN; 8-OH-DPAT; ADDICTION; ADHD; AMPHETAMINE; APOMORPHINE; ATTENTION DEFICIT HYPERACTIVITY DISORDER; BAY×3702; DOPAMINE; DORSAL RAPHE; DR; GABA; GAMMA-AMINOBUTYRIC ACID; HOMOVANILLIC ACID; HVA; MEDIAN RAPHE; MR; N-METHYL-D-ASPARTATE; N-[2-[4-(2-METHOXYPHENYL)-1-PIPERAZINYL] ETHYL]- N-(2-PYRIDYL) CYCLOHEXANECARBOXAMIDE; NMDA; PSYCHOSIS; R-(-)-2-{4-[(CHROMAN-2-YLMETHYL)- AMINO]-BUTYL}-1,1-DIOXO-BENZO[D] ISOTHIAZOL ONE HCL; SN; SUBSTANTIA NIGRA; VENTRAL TEGMENTAL AREA; VTA; WAY 100135; WAY100635;

ANIMALS; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; NERVOUS SYSTEM DISEASES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN 5-HT1 RECEPTOR AGONISTS;

EID: 84882780966     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.07.015     Document Type: Review

References (166)

1. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998, 155:761-767.
2. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L.S., et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A 2000, 97:8104-8109.
3. Ago Y., Nakamura S., Uda M., Kajii Y., Abe M., Baba A., et al. Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice. Neuropharmacology 2006, 51:914-922.
4. Ahmed S.H., Cador M. Dissociation of psychomotor sensitization from compulsive cocaine consumption. Neuropsychopharmacology 2006, 31:563-571.
5. Ahmed I., Thorpy M. Clinical features, diagnosis and treatment of narcolepsy. Clin Chest Med 2010, 31:371-381.
6. Arborelius L., Chergui K., Murase S., Nomikos G.G., Hook B.B., Chouvet G. The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Arch Pharmacol 1993, 347:353-362.
7. Arborelius L., Nomikos G.G., Hacksell U., Svensson T.H. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Physiol Scand 1993, 148:465-466.
8. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two levels of d-amphetamine. Eur J Pharmacol 1995, 283:55-62.
9. Arvidsson L.E., Hacksell U., Nilsson J.L., Hjorth S., Carlsson A., Lindberg P., et al. 8-Hydroxy-2-(di-n-propylamino)tetralin, a new centrally acting 5-hydroxytryptamine receptor agonist. J Med Chem 1981, 24:921-923.
10. Arvidsson L.E., Johansson A.M., Hacksell U., Nilsson J.L., Svensson K., Hjorth S., et al. (+)-Cis-8-Hydroxy-1-methyl-2-(di-n-propylamino)tetralin: a potent and highly stereoselective 5-hydroxytryptamine receptor agonist. J Med Chem 1987, 30:2105-2109.
11. Assie M.B., Koek W. Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties. Eur J Pharmacol 1996, 304:15-21.
12. Assié M.B., Koek W. [(3)H]-8-OH-DPAT binding in the rat brain raphe area: involvement of 5-HT(1A) and non-5-HT(1A) receptors. Br J Pharmacol 2000, 130:1348-1352.
13. Assie M.B., Ravailhe V., Faucillon V., Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 2005, 315:265-272.
14. Azmitia E.C., Segal M. An autoradiographic analysis of the differential ascending projections of the dorsal and median raphe nuclei in the rat. J Comp Neurol 1978, 179:641-667.
15. Bantick R.A., Deakin J.F., Grasby P.M. 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?. J Psychopharmacol 2001, 15:37-46.
16. Batool F., Ahmed S., Haleem D.J. Dietary supplementations of amino acids: evidence for enhanced serotonergic functions following haloperidol withdrawal in rat medial prefrontal cortex. J Coll Physicians Surg Pak 2009, 19:139-145.
17. Batool F., Shah A.H., Ahmed S.D., Saify Z.S., Haleem D.J. Protective effects of aqueous fruit extract from Sea Buckthorn (Hippophae rhamnoides L. Spp. Turkestanica) on haloperidol-induced orofacial dyskinesia and neuronal alterations in the striatum. Med Sci Monit 2010, 16:BR285-BR292.
18. Baumeister A.A., Henderson K., Pow J.L., Advokat C. The early history of the neuroscience of attention-deficit/hyperactivity disorder. J Hist Neurosci 2012, 21:263-279.
19. Berridge K.C., Robinson T.E., Aldridge J.W. Dissecting components of reward: 'liking', 'wanting', and learning. Curr Opin Pharmacol 2009, 9:65-73.
20. Bockaert J., Dumuis A., Bouhelal R., Sebben M., Cory R.N. Piperazine derivatives including the putative anxiolytic drugs, buspirone and ipsapirone, are agonists at 5-HT1A receptors negatively coupled with adenylate cyclase in hippocampal neurons. Naunyn Schmiedebergs Arch Pharmacol 1987, 335:588-592.
21. Bonaventure P., Nepomuceno D., Kwok A., Chai W., Langlois X., Hen R., et al. Reconsideration of 5-hydroxytryptamine (5-HT)(7) receptor distribution using [(3)H]5-carboxamidotryptamine and [(3)H]8-hydroxy-2-(di-n-propylamino)tetraline: analysis in brain of 5-HT(1A) knockout and 5-HT(1A/1B) double-knockout mice. J Pharmacol Exp Ther 2002, 302:240-248.
22. Bortolozzi A., Díaz-Mataix L., Toth M., Celada P., Artigas F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology 2007, 191:745-758.
23. Bortolozzi A., Masana M., Díaz-Mataix L., Cortés R., Scorza M.C., Gingrich J.A., et al. Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT (1A) receptors but not 5-HT(2A) receptors. Int J Neuropsychopharmacol 2010, 13:1299-1314.
24. Braga P.Q., Dias F.R., Carey R.J., Carrera M. Low dose apomorphine induces context-specific sensitization of hypolocomotion without conditioning: support for a new state dependent retrieval hypothesis of drug conditioning and sensitization. Pharmacol Biochem Behav 2009, 93:128-133.
25. Braga P.Q., Dias F.R., Carey R.J., Carrera M.P. Behavioral sensitization to dopaminergic inhibitory and stimulatory effects induced by low vs. high dose apomorphine treatments: an unconventional dose and response reversal sensitization challenge test reveals sensitization mechanisms. Behav Brain Res 2009, 204:169-174.
26. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997, 94:2569-2574.
27. Carey R.J., Depalma G., Damianopoulos E., Muller C.P., Huston J.P. The 5-HT1A receptor and behavioral stimulation in the rat: effects of 8-OHDPAT on spontaneous and cocaine-induced behavior. Psychopharmacology 2004, 177:46-54.
28. Clark M.S., McDevitt R.A., Neumaier J.F. Quantitative mapping of tryptophan hydroxylase-2, 5-HT1A, 5-HT1B, and serotonin transporter expression across the anteroposterior axis of the rat dorsal and median raphe nuclei. J Comp Neurol 2006, 498:611-623.
29. Crosby M.I., Bradshaw D.A., McLay R.N. Severe mania complicating treatment of narcolepsy with cataplexy. J Clin Sleep Med 2011, 7:214-216.
30. Dahlström A., Fuxe K. Evidence for the existence of monoamine containing neurons in the central nervous system: demonstration of monoamines in the cell bodies of brainstem neurons. Acta Physiol Scand 1964, 232(Suppl. 62):1-55.
31. De La Garza R., Cunningham K.A. The effects of the 5- hydroxytryptamine1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin on spontaneous activity, cocaine-induced hyperactivity and behavioral sensitization: a microanalysis of locomotor activity. JPET 2000, 292:610-617.
32. de Matos L.W., Carey R.J., Carrera M.P. Apomorphine conditioning and sensitization: the paired/unpaired treatment order as a new major determinant of drug conditioned and sensitization effects. Pharmacol Biochem Behav 2010, 96:317-324.
33. De Vries T.J., Schoffelmeer A.N., Binnekade R., Mulder A.H., Vanderschuren L.J. Drug-induced reinstatement of heroin- and cocaine-seeking behaviour following long-term extinction is associated with expression of behavioural sensitization. Eur J Neurosci 1998, 10:3565-3571.
34. Deleu D., Hanssens Y., Northway M.G. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson's disease. Drugs Aging 2004, 21:687-709.
35. Derosa G., Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf 2012, 11:459-471.
36. Dias F.R., Carey R.J., Carrera M.P. Apomorphine-induced context-specific behavioural sensitization is prevented by the D1 antagonist SCH-23390 but potentiated and uncoupled from contextual cues by the D2 antagonist sulpiride. Psychopharmacology 2010, 209:137-151.
37. Diaz-Mataix L., Scorza M.C., Bortolozzi A., Toth M., Celada P., Artigas F. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 2005, 25:10831-10843.
38. Doherty M.D., Pickel V.M. Targeting of serotonin 1A receptors to dopaminergic neurons within the parabrachial subdivision of the ventral tegmental area in rat brain. J Comp Neurol 2001, 433:390-400.
39. Downs A.W., Eddy N.B. The effect of repeated doses of cocaine in the rat. J Pharmacol Exp Ther 1932, 46:199-202.
40. Easton N., Steward C., Marshall F., Fone K., Marsden C. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology 2007, 52:405-414.
41. Elia J. Attention deficit/hyperactivity disorder: pharmacotherapy. Psychiatry (Edgmont) 2005, 2:27-35.
42. Elliott J., Reynolds G.P. Agonist-stimulated GTPgamma[35S] binding to 5-HT(1A) receptors in human post-mortem brain. Eur J Pharmacol 1999, 386:313-315.
43. Ferrario C.R., Gorny G., Crombag H.S., Li Y., Kolb B., Robinson T.B. Neural and behavioral plasticity associated with the transition from controlled to escalated cocaine use. Biol Psychiatry 2005, 58:751-759.
44. Fletcher P.J., Lê A.D., Higgins G.A. Serotonin receptors as potential targets for modulation of nicotine use and dependence. Prog Brain Res 2008, 172:361-383.
45. Fornal C.A., Metzler C.W., Gallegos R.A., Veasey S.C., McCreary A.C., Jacobs B.L. WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135. J Pharmacol Exp Ther 1996, 278:752-762.
46. Frankel J.P., Lees A.J., Kempster P.A., Stern G.M. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 1990, 53:96-101.
47. Futamura T., Akiyama S., Sugino H., Forbes A., McQuade R.D., Kikuchi T. Aripiprazole attenuates established behavioral sensitization induced by methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1115-1119.
48. Glaser T., Traber J. Buspirone: action on serotonin receptors in calf hippocampus. Eur J Pharmacol 1983, 88:137-138.
49. Gronier B. Involvement of glutamate neurotransmission and N-methyl-d-aspartate receptor in the activation of midbrain dopamine neurons by 5-HT1A receptor agonists: an electrophysiological study in the rat. Neuroscience 2008, 156:995-1004.
50. Haleem D.J. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia. J Coll Physicians Surg Pak 2006, 16:556-562.
51. Haleem D.J. Exaggerated feedback control decreases brain serotonin concentration and elicits hyperactivity in a rat model of diet-restriction-induced anorexia nervosa. Appetite 2009, 52:44-50.
52. Haleem D.J. Neurochemistry, neuropharmacology and behavior 2010, VDM Publishers Germany.
53. Haleem D.J., Khan N.H. Enhancement of serotonin-1A receptor dependent responses following withdrawal of haloperidol in rats. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:645-651.
54. Haleem D.J., Kennett G.A., Curzon G. Hippocampal 5-hydroxytryptamine synthesis is greater in female rats than in males and more decreased by the 5-HT1A agonist 8-OH-DPAT. J Neural Transm Gen Sect 1990, 79:93-101.
55. Haleem D.J., Batool F., Khan N.H., Kamil N., Ali O., Saify Z.S., et al. Differences in the effects of haloperidol and clozapine on brain serotonin and dopamine metabolism and on tests related to extrapyramidal functions in rats. Med Sci Monit 2002, 8:BR354-BR361.
56. Haleem D.J., Naz H., Parveen T., Haider S., Ahmed S.P., Khan N.H., et al. Serotonin and serotonin 1-A receptors in the failure of ethanol-treated rats to adapt to a repeated stress schedule. J Stud Alcohol 2002, 63:389-396.
57. Haleem D.J., Shireen E., Haleem M.A. Somatodendritic and postsynaptic serotonin-1A receptors in the attenuation of haloperidol-induced catalepsy. Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:1323-1329.
58. Haleem D.J., Hasnat A., Shireen E., Khan A., Haleem Dopamine and serotonin neurotransmission in the reinforcing effects of alcohol and apomorphine. J Coll Physician Surg Pak 2005, 15:458-462.
59. Haleem D.J., Samad N., Haleem M.A. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. Pharmacol Biochem Behav 2007, 87:115-121.
60. Haleem D.J., Samad N., Haleem M.A. Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study. Behav Pharmacol 2007, 18:147-153.
61. Hamamura T., Akiyama K., Akimoto K., Kashihara K., Okumura K., Ujike H. Coadministration of either a selective D1 or D2 dopamine antagonist with methamphetamine prevents methamphetamine-induced behavioral sensitization and neurochemical change, studied by in vivo intracerebral dialysis. Brain Res 1991, 546:40-46.
62. Heal D.J., Smith S.L., Kulkarni R.S., Rowley H.L. New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD. Pharmacol Biochem Behav 2008, 90:184-197.
63. Hervas I., Bel N., Fernandez A.G., Palacios J.M., Artigas F. In vivo control of 5-hydroxytryptamine release by terminal autoreceptors in rat brain areas differentially innervated by the dorsal and median raphe nuclei. Naunyn Schmiedebergs Arch Pharmacol 1998, 358:315-322.
64. Hillegaart V. Effects of local application of 5-HT and 8-OH-DPAT into the dorsal and median raphe nuclei on motor activity in the rat. Physiol Behav 1990, 48:143-148.
65. Himeno E., Ohyagi Y., Ma L., Nakamura N., Miyoshi K., Sakae N., et al. Apomorphine treatment in Alzheimer mice promoting amyloid-β degradation. Ann Neurol 2011, 69:248-256.
66. Hodgkins P., Shaw M., Coghill D., Hechtman L. Amphetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options. Eur Child Adolesc Psychiatry 2012, 21:477-492.
67. Hoffman D.C., Wise R.A. Lack of cross-sensitization between the locomotor-activating effects of bromocriptine and those of cocaine or heroin. Psychopharmacology (Berl) 1993, 110:402-408.
68. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002, 71:533-554.
69. Ichikawa J., Meltzer H.Y. The effect of serotonin (1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res 2000, 858:252-263.
70. Ichikawa J., Kuroki T., Kitchen M.T., Meltzer H.Y. R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. Eur J Pharmacol 1995, 287:179-184.
71. Ikram H., Haleem D.J. Attenuation of apomorphine-induced sensitization by buspirone. Pharmacol Biochem Behav 2011, 99:444-450.
72. Ikram H., Ahmad S., Haleem D.J. Effects of apomorphine on locomotive activity and monoamine metabolism: a dose related study. Pak J Pharm Sci 2011, 24:315-321.
73. Jackson D.M., Johansson C., Lindgren L.M., Bengtson A. Dopamine receptor antagonists block amphetamine and phencyclidine-induced motor stimulation in rats. Pharmacol Biochem Behav 1994, 41:465-471.
74. Kahlig K.M., Binda F., Khoshbouei H., Blakely R.D., McMahon D.G., Javitch J.A., et al. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci U S A 2005, 102:3495-3500.
75. Kalivas P.W., Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 1991, 16:223-244.
76. Kalivas P.W., Peters J., Knackstedt L. Animal models and brain circuits in drug addiction. Mol Interv 2006, 6:339-344.
77. Kaneko Y., Kashiwa A., Ito T., Ishii S., Umino A., Nishikawa T. Selective serotonin reuptake inhibitors, fluoxetine and paroxetine, attenuate the expression of the established behavioral sensitization induced by methamphetamine. Neuropsychopharmacology 2007, 32:658-664.
78. Kelland M.D., Freeman A.S., Chiodo L.A. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 1990, 253:803-811.
79. Knacksted L.A., Kalvis P.W. Extended access to cocaine self-administration enhances drug-primed reinstatement but not behavioral sensitization. J Pharmacol Exp Ther 2007, 322:1103-1109.
80. Köhler C., Steinbusch H. Identification of serotonin and non-serotonin-containing neurons of the mid-brain raphe projecting to the entorhinal area and the hippocampal formation. A combined immunohistochemical and fluorescent retrograde tracing study in the rat brain. Neuroscience 1982, 7:951-975.
81. Kuipers W., Kruse C.G., van Wijngaarden I., Standaar P.J., Tulp M.T., Veldman N., et al. 5-HT1A-versus D2-receptor selectivity of flesinoxan and analogous N4-substituted N1-arylpiperazines. J Med Chem 1997, 40:300-312.
82. Kuribara H. Can post treatment with the selective dopamine D2 antagonist, YM-09151-2, inhibit induction of methamphetamine sensitization? Evaluation by ambulatory activity in mice. Pharmacol Biochem Behav 1994, 49:323-326.
83. Kuribara H. Dopamine D1 receptor antagonist SCH 23390 retards methamphetamine sensitization in both combined administration and early posttreatment schedules in mice. Pharmacol Biochem Behav 1995, 52:759-763.
84. Kuroki T., Ichikawa J., Dai J., Meltzer H.Y. R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced serotonin and dopamine release in rat medial prefrontal cortex. Brain Res 1996, 743:357-361.
85. Kuroki T., Dai J., Meltzer H.Y., Ichikawa J. R(+)-8-OH-DPAT, a selective 5-HT(1A) receptor agonist, attenuated amphetamine-induced dopamine synthesis in rat striatum, but not nucleus accumbens or medial prefrontal cortex. Brain Res 2000, 872:204-207.
86. Laine K., Ahokoski O., Huupponen R., Hanninen J., Palovaara S., Ruuskanen J., et al. Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone. Eur J Clin Pharmacol 2003, 59:761-766.
87. Lanteri C., Hernández Vallejo S.J., Salomon L., Doucet E.L., Godeheu G., Torrens Y., et al. Inhibition of monoamine oxidases desensitizes 5-HT1A autoreceptors and allows nicotine to induce a neurochemical and behavioral sensitization. J Neurosci 2009, 29:987-997.
88. Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q J Nucl Med 1998, 42:211-221.
89. Laruelle M. The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain Res Brain Res Rev 2000, 31:371-384.
90. Lejeune F., Millan M.J. Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT) 1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S 15535. Synapse 1998, 30:172-180.
91. Lenoir M., Ahmed S.H. Heroin-induced reinstatement is specific to compulsive heroin use and dissociable from heroin reward and sensitization. Neuropsychopharmacology 2007, 32:616-624.
92. Lucas G., Bonhomme N., De Deurwaerdère P., Le Moal M., Spampinato U. 8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release. Psychopharmacology (Berl) 1997, 131:57-63.
93. Ma L., Ohyagi Y., Nakamura N., Iinuma K.M., Miyoshi K., Himeno E., et al. Activation of glutathione peroxidase and inhibition of p53-related apoptosis by apomorphine. J Alzheimers Dis 2011, 27:225-237.
94. Marcotte E.R., Pearson D.M., Srivastav L.K. Animal models of schizophrenia: a critical review. J Psychiatry Neurosci 2001, 26:395-410.
95. Matsuda T., Yoshikawa T., Suzuki M., Asano S., Somboonthum P., Takuma K., et al. Novel benzodioxan derivative, 5-(3-[((2S)-1,4-benzodioxan-2- ylmethyl) amino] propoxy)-1,3-benzodioxole HCl (MKC-242), with a highly potent and selective agonist activity at rat central serotonin1A receptors. Jpn J Pharmacol 1995, 69:357-366.
96. Matthews P.R., Harrison P.J. A morphometric, immunohistochemical, and in situ hybridization study of the dorsal raphe nucleus in major depression, bipolar disorder, schizophrenia, and suicide. J Affect Disord 2012, 137:125-134.
97. Mattingly B.A., Gotsick J.E. Conditioning and experiential factors affecting the development of sensitization to apomorphine. Behav Neurosci 1989, 103:1311-1317.
98. May D.E., Kratochvil C.J. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs 2010, 70:15-40.
99. McCreary A.C., Jones C.A. Antipsychotic medication: the potential role of 5-HT1A receptor agonism. Curr Pharm Des 2010, 16:516-521.
100. McCreary A.C., Marsden C.A. Cocaine-induced behaviour: dopamine D1 receptor antagonism by SCH 23390 prevents expression of conditioned sensitisation following repeated administration of cocaine. Neuropharmacology 1993, 32:387-391.
101. Meltzer H.Y., Sumiyoshi T. Does stimulation of 5-HT1A receptors improve cognition in schizophrenia?. Behav. Brain Res 2008, 195:98-102.
102. Meltzer H.Y., Li Z., Kaneda Y., Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:1159-1172.
103. Millan M.J. Improving the treatment of schizophrenia: focus on serotonin (5-HT1A) receptors. J Pharmacol Exp Ther 2000, 295:853-861.
104. Narita M., Akai H., Nagumo Y., Sunagawa N., Hasebe K., Nagase H. Implication of protein kinase C in the nucleus accumbens in the development of sensitization to methamphetamine in rats. Neuroscience 2004, 127:941-948.
105. Neal-Beliveau B.S., Joyce J.N., Lucki I. Serotonergic involvement in haloperidol-induced catalepsy. J Pharmacol Exp Ther 1993, 265:207-217.
106. Nestler E.J. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001, 2:119-128.
107. Newman-Tancredi A., Assié M.B., Leduc N., Ormière A.M., Danty N., Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 2005, 8:341-356.
108. Nishikawa T., Matagata N., Takashima M., Toru M. Behavioral sensitization and relative hyperresponsiveness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment. Eur J Pharmacol 1983, 88:195-203.
109. Ondo W.G., Hunter C., Ferrara J.M., Mostile G. Apomorphine injections: predictors of initial common adverse events and long term tolerability. Parkinsonism Relat Disord 2012, 18:619-622.
110. Opler L.A., Frank D.M., Ramirez P.M. Psychostimulants in the treatment of adults with psychosis and attention deficit disorder. Ann N Y Acad Sci 2001, 931:297-301.
111. Parker G., Brotchie H. Do the old psychostimulant drugs have a role in managing treatment-resistant depression?. Acta Psychiatr Scand 2010, 121:308-314.
112. Patrick S.L., Thompson T.L., Walker J.M., Patrick R.L. Concomitant sensitization of amphetamine-induced behavioral stimulation and in vivo dopamine release from rat caudate nucleus. Brain Res 1991, 538:343-346.
113. Pazos A., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain: I. Serotonin-1 receptors. Brain Res 1985, 346:205-230.
114. Peleg-Raibstein D., Yee B.K., Feldon J., Hauser J. The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms?. Psychopharmacology (Berl) 2009, 206:603-621.
115. Pereira F.C., Cunha-Oliveira T., Viana S.D., Travassos A.S., Nunes S., Silva C., et al. Disruption of striatal glutamatergic/GABAergic homeostasis following acute methamphetamine in mice. Neurotoxicol Teratol 2012, 34:522-529.
116. Piercey M.F., Tang A.H., Lahti R.A., VonVoigtlander P.F., Schreur P.J., McCall R.B., et al. Pharmacology of a mixed 5-hydroxytryptamine1A/dopamine agonist. J Pharmacol Exp Ther 1983, 68:304-310.
117. Poewe W. Treatments for Parkinson disease-past achievements and current clinical needs. Neurology 2009, 72:S65-S73.
118. Poewe W., Wenning G.K. Apomorphine: an underutilized therapy for Parkinson's disease. Mov Disord 2000, 15:789-794.
119. Polanczyk G., de Lima M.S., Horta B.L., Biederman J., Rohde L.A. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007, 164:942-948.
120. Pompeiano M., Palacios J.M., Mengod G. Distribution and cellular localization of mRNA coding for 5-HT1A receptor in the rat brain: correlation with receptor binding. J Neurosci 1992, 12:440-453.
121. Post R.M., Rose H. Increasing effects of repetitive cocaine administration in the rat. Nature 1976, 260:731.
122. Prinssen E.P., Kleven M.S., Koek W. Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects. Psychopharmacology (Berl) 1999, 144:20-29.
123. Prinssen E.P., Colpaert F.C., Koek W. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 2002, 453:217-221.
124. Przegaliñski E., Filip M. Stimulation of serotonin (5-HT) 1A receptors attenuates the locomotor, but not the discriminative, effects of amphetamine and cocaine in rats. Behav Pharmacol 1997, 8:699-706.
125. Przegalinski E., Siwanowicz J., Baran L., Filip M. Activation of serotonin (5-HT) 1A receptors inhibits amphetamine sensitization in mice. Life Sci 2000, 66:1011-1019.
126. Riad M., Garcia S., Watkins K.C., Jodoin N., Doucet E., Langlois X. Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comp Neurol 2000, 417:181-194.
127. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 1986, 11:157-198.
128. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive sensitization theory of addiction. Brain Res Brain Res Rev 1993, 18:247-291.
129. Robinson T.E., Berridge K.C. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 2000, 95:S91-S117.
130. Robinson T.E., Berridge K.C. Incentive-sensitization and addiction. Addiction 2001, 96:103-114.
131. Robinson T.E., Berridge K.C. Addiction. Annu Rev Psychol 2003, 54:25-53.
132. Robinson T.E., Jurson P.A., Bennett J.A., Bentgen K.M. Persistent sensitization of dopamine neurotransmission in ventral striatum (nucleus accumbens) produced by prior experience with (+)-amphetamine: a microdialysis study in freely moving rats. Brain Res 1988, 462:211-222.
133. Rollema H., Lu Y., Schmidt A.W., Zorn S.H. Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. Eur J Pharmacol 1997, 338:R3-R5.
134. Rollema H., Lu Y., Schmidt A.W., Sprouse J.S., Zorn S.H. 5-HT (1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 2000, 48:229-237.
135. Rowlett J.K., Mattingly B.A., Bardo M.T. Repeated quinpirole treatment: locomotor activity, dopamine synthesis, and effects of selective dopamine antagonists. Synapse 1995, 20:209-216.
136. Samad N., Batool F., Haleem D.J. Neurochemical and behavioral effects of 8-OH-DPAT following exposure to restraint stress in rats. Pharmacol Rep 2007, 59:173-180.
137. Savli M., Bauer A., Mitterhauser M., Ding Y.S., Hahn A., Kroll T., et al. Normative database of the serotonergic system in healthy subjects using multi-tracer PET. Neuroimage 2012, 63:447-459.
138. Schwartz T.L., Nihalani N., Virk S., Jindal S., Chilton M. Psychiatric medication-induced obesity: treatment options. Obes Rev 2004, 5:233-238.
139. Sharp T., Bramwell S.R., Hjorth S., Grahame-Smith D.G. Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis. Br J Pharmacol 1989, 98:989-997.
140. Shireen E., Haleem D.J. Motor effects of buspirone: relationship with dopamine and serotonin in the striatum. J Coll Physicians Surg Pak 2005, 15:753-756.
141. Shuto T., Nishi A. Treatment of the psychostimulant-sensitized animal model of schizophrenia. CNS Neurosci Ther 2011, 17:133-139.
142. Stark A.D., Jordan S., Allers K.A., Bertekap R.L., Chen R., Kannan T.M. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology 2007, 190:373-382.
143. Steed E., Jones C.A., McCreary A.C. Serotonergic involvement in methamphetamine-induced locomotor activity: a detailed pharmacological study. Behav Brain Res 2011, 220:9-19.
144. Stephans S.E., Yamamoto B.Y. Effect of repeated methamphetamine administrations on dopamine and glutamate efflux in rat prefrontal cortex. Brain Res 1995, 700:99-106.
145. Sugimoto Y., Takashima N., Noma T., Yamada J. Inhibitory effects of the 5-HT(1A) receptor agonist buspirone on stress-induced hyperglycemia in mice: involvement of insulin and a buspirone metabolite, 1-(2-pyrimidinyl)piperazine (1-PP). Biol Pharm Bull 2005, 28:733-735.
146. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 2005, 75:406-433.
147. Sumiyoshi T., Park S., Jayathilake K., Roy A., Ertugrul A., Meltzer H.Y. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2007, 95:158-168.
148. Sunderland T., Cohen R.M., Molchan S., Lawlor B.A., Mellow A.M., Newhouse P.A., et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994, 51:607-615.
149. Szechtman H., Dai H., Mustafa S., Einat H., Sullivan R.M. Effects of dose and interdose interval on locomotor sensitization to the dopamine agonist quinpirole. Pharmacol Biochem Behav 1994, 48:921-928.
150. Tadori Y., Miwa T., Tottori K., Burris K.D., Stark A., Mori T. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 2005, 515:10-19.
151. Tadori Y., Kitagawa H., Forbes R.A., McQuade R.D., Stark A., Kikuchi T. Difference in agonist/antagonist properties at human dopamine D2 receptors between aripiprazole, bifeprunox and SDZ 208-912. Eur J Pharmacol 2007, 574:103-111.
152. Tauscher J., Kapur S., Verhoeff N.P., Hussey D.F., Daskalakis Z.J., Tauscher-Wisniewski S., et al. Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch Gen Psychiatry 2002, 59:514-520.
153. Thorpy M. Current concepts in the etiology, diagnosis and treatment of narcolepsy. Sleep Med 2001, 2:5-17.
154. Tien L.T., Ho J.K., Loh H.H., Ma T. Role of m-opioid receptor in modulation of preproenkephalin mRNA expression and opioid and dopamine receptor binding in methamphetamine-sensitized mice. J Neurosci Res 2007, 85:673-680.
155. Trivedi M.S., Jarbe T. A brief review on recent developments in animal models of schizophrenia. Indian J Pharm 2011, 43:375-380.
156. Ujike H. Stimulant-induced psychosis and schizophrenia: the role of sensitization. Curr Psychiatry Rep 2002, 4:177-184.
157. Ujike H., Sato M. Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis. Ann N Y Acad Sci 2004, 1025:279-287.
158. Vanderschuren L.J., Kalivas P.W. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 2000, 151:99-120.
159. Vanderschuren L.J., Pierce R.C. Sensitization processes in drug addiction. Curr Top Behav Neurosci 2010, 3:179-195.
160. Vanina Y., Podolskaya A., Sedky K., Shahab H., Siddiqui A., Munshi F., et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 2002, 53:842-847.
161. Vezina P. Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. Neurosci Biobehav Rev 2004, 27:827-839.
162. Warbritton J.D., Stewart R.M., Baldessarini R.J. Decreased locomotor activity and attenuation of amphetamine hyperactivity with intraventricular infusion of serotonin in the rat. Brain Res 1978, 143:373-382.
163. Wolf M.E., White F.J., Nassar R., Brooderson R., Khansa M.R. Differential development of autoreceptor subsensitivity and enhanced dopamine release during amphetamine sensitization. J Pharmacol Exp Ther 1993, 264:249-255.
164. Wong D.F., Wagner H.N., Tune L.E., Dannals R.F., Pearlson G.D., Links J.M., et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986, 234:1558-1563. [Erratum in: Science (1987) 235, 623].
165. Yoo J.H., Lee H.K., Kim H.C., Lee S.Y., Jang C.G. GABA (A) receptors mediate the attenuating effects of a 5-HT(3) receptor antagonist on methamphetamine-induced behavioral sensitization in mice. Synapse 2010, 64:274-279.
166. Yoshimoto K., McBride W. Regulation of nucleus accumbens dopamine release by the dorsal raphe nucleus in the rat. Neurochem Res 1992, 17:401-407.